SEARCH

SEARCH BY CITATION

References

  • 1
    Lerner AB, Case JD, Takahashi Y et al. Isolation of melatonin the pineal gland factor that lightens the pinealocytes. J Am Chem Soc 1958; 80: 2587.
  • 2
    Reiter RJ. Melatonin: that ubiquitously acting pineal hormone. News Physiol Sci 1991; 6: 223227.
  • 3
    Manchester LC, Poeggeler B, Alvares FL et al. Melatonin immunoreactivity in the photosynthetic prokaryote, Rhodospirillum rubrum implication for an ancient antioxidant system. Cell Mol Biol Res 1995; 41: 391395.
  • 4
    Poeggeler B, Balzer I, Hardeland R et al. Pineal hormone melatonin oscillates also in the dinoflagellate, Gonyaulax polydrea. Naturwissenschaten 1991; 78: 268269.
  • 5
    Hattori A, Migitaka H, Masayake I et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 1995; 35: 627634.
  • 6
    De Vries MW, Peeters FP. Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression. J Nerv Ment Dis 1997; 185: 201202.
  • 7
    Jan JE, O'donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res 1996; 21: 193199.
  • 8
    Garfinkel D, Laudon M, Nof D et al. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet 1995; 346: 541544.
  • 9
    Morgan PJ, Williams LM. Central melatonin receptors: implication for a mode of action. Experientia 1989; 45: 955.
  • 10
    List of Orphan Drug Designation and Approval. Office of Orphan Products Development, Food and Drug Administration, Rockville, MD, last rev August 2002.
  • 11
    Nowak JZ, Zawilska JB. Melatonin and its physiological and therapeutic properties. Pharm World Sci 1998; 20: 1827.
  • 12
    Sandyk R. Melatonin supplements for aging. Int J Neurosci 1996; 87: 219224.
  • 13
    Pappolla MA, Reiter RJ, Bryant-thomas TK et al. Oxidative mediated neurodegeneration in Alzheimer's disease: melatonin and related antioxidants as neuroprotective agents. Curr Med Chem 2003; 3: 233243.
  • 14
    Lissoni P, Meregalli S, Nasetto L et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996; 53: 4346.
  • 15
    Lissoni P, Barni S, Brivio F et al. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 1995; 52: 360362.
  • 16
    Barni S, Lissoni P, Cazzaniga M et al. Randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995; 52: 243245.
  • 17
    Aldeghi R, Lissoni P, Barni SL et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994; 30: 167170.
  • 18
    Reiter RJ, Carneiro RCG, Oh CS. Melatonin in relation to cellular antioxidative defence mechanisms. Horm Metab Res 1997; 29: 343392.
  • 19
    Tan DX, Chen LD, Poeggler B et al. A potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 5760.
  • 20
    Vijayalaxmi BZ, Reiter RJ, Sewerynek E et al. Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat Res 1995; 346: 2331.
  • 21
    Livrea MA, Tesoriere L, D'arpa D et al. Reaction of melatonin with lipoperxyl radicals in phospholipid bilayers. Free Rad Biol Med 1997; 23: 706711.
  • 22
    Marshall KA, Reiter RJ, Poeggeler B et al. Evaluation of the antioxidant activity of melatonin in vitro. Free Rad Biol Med 1996; 21: 307315.
  • 23
    Turjanski AG, Leonik F, Estrin DA et al. Scavenging of NO by melatonin. J Am Chem Soc 2000; 122: 10,46810,469.
  • 24
    Uppu R, Prior WA. Nitrosation of 1,2-phenylenediamine by peroxynitrite/CO2: evidence for a free radical mechanism. J Am Chem Soc 1999; 121: 97389739.
  • 25
    Barchas J, Da Costa F, Spector S. Acute pharmacology of melatonin. Nature 1967; 214: 919920.
  • 26
    Allegra M, Reiter RJ, Tan DX et al. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34: 110.
  • 27
    Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interaction. Endocrine Rev 1991; 12: 151180.
  • 28
    Vakkuri O, Tervo J, Luttinen R et al. A Cyclic isomer of 2–hydroxymelatonin: a novel metabolite of melatonin. Endocrinology 1987; 120: 24532459.
  • 29
    Tan DX, Manchester LC, Reiter RJ et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochim Biophys Res Commun 1998; 253: 614620.
  • 30
    Dellegar SM, Murphy SA, Bourne AE et al. Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Biochem Biophys Res Commun 1999; 257: 431439.
  • 31
    Tesoriere L, Avellone G, Ceraulo L et al. Oxidation of melatonin by oxoferryl hemoglobin: a mechanistic study. Free Radical Research 2001; 35: 633642.
  • 32
    Ceraulo L, Ferrugia M, Tesoriere L et al. Interactions of melatonin with membrane models: portioning of melatonin in AOT and Lecithin Reversed Micelles. J Pineal Res 1999; 26: 108112.
  • 33
    Bongiorno D, Ceraulo L, Mele A et al. Structural and physicochemical characterization of the inclusion complexes of cyclomaltooligosaccharides (cyclodextrins) with melatonin. Carbohydr Res 2002; 337: 743754.
  • 34
    Bongiorno D, Ceraulo L, Mele A et al. Guest-to-host-proton transfer in melatonin-beta-cyclodextrin inclusion complex by ionspray, fast atom bombardament and tandem mass spectrometry. J Mass Spectrom 2001; 36: 11891194.
  • 35
    Patel RP, Svistunenko DA, Darley-usma VM et al. Redox cycling of human methemoglobin by H2O2 yields persistent ferryl iron and protein based radicals. Free Radical Res Comm 1996; 22: 117123.
  • 36
    Diamantini G, Tarzia G, Spadoni G et al. Metastable ion studies in the characterization of melatonin isomers. Rapid Commun Mass Spectrom 1998; 12: 15381542.
  • 37
    Remers WA. Properties and reactions of indoles isoindoles, and their hydrogenated derivatives. In: The Chemistry of Heterocyclic Compounds 25th Volume: Indoles Part I. WeissbergerA, TaylorEC, eds, John Wiley & Sons, New York, 1972; pp. 35.
  • 38
    Cardinali DP, Ladiezesky MG, Boggio V et al. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34: 8187.
  • 39
    Cheung TF. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 2003; 34: 153160.
  • 40
    Sahna E, Acet A, Ozer MK et al. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 2002; 33: 234238.